Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2018 11:32 ET | Source: Opthea Limited

Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial

MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, is pleased to...
November 14, 2018 05:30 ET | Source: Opthea Limited

Opthea Completes Patient Recruitment Ahead of Schedule in Phase 2b Wet AMD Clinical Trial

MELBOURNE, Australia, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today...
October 29, 2018 05:30 ET | Source: Opthea Limited

Opthea Provides Update on Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum

MELBOURNE, Australia, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to provide an update on...
October 26, 2018 05:30 ET | Source: Opthea Limited

Opthea Reports Positive Three-Month Data from Phase 1b Dose Escalation Study for OPT-302 in Diabetic Macular Edema

MELBOURNE, Australia, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing innovative biologic therapies to treat retinal diseases, today...
October 24, 2018 05:30 ET | Source: Opthea Limited

Opthea To Present Update at the Ophthalmology Innovation Summit in Chicago

MELBOURNE, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
September 24, 2018 05:30 ET | Source: Opthea Limited

Opthea to Host Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum in New York City

MELBOURNE, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to announce that it will host...
September 14, 2018 05:30 ET | Source: Opthea Limited

Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting

MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat...
September 05, 2018 05:30 ET | Source: Opthea Limited

Opthea Receives Positive Interim Review from Independent Safety Committee in Phase 2b Wet AMD Clinical Trial

MELBOURNE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, today...
July 30, 2018 06:00 ET | Source: Opthea Limited

Opthea Doses First Patient in Phase 2a Trial for OPT-302 in Diabetic Macular Edema

MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, has...
July 26, 2018 05:30 ET | Source: Opthea Limited

Opthea Meets Primary Safety Objective with OPT-302 in Phase 1b Diabetic Macular Edema Clinical Trial

MELBOURNE, Australia, July 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases,...